The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on March ....
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Promoter Hima Bindu Potluri has created a fresh encumbrance of 30,00,000 equity shares (3.54% of total share capital) in SMS Pharmaceuticals on March 25, 2025, in the form of a Non-Disposal Undertaking (NDU) with Vistra ITCL (India) Ltd as Debenture Trustee. The encumbrance is against Non-Convertible Debentures issued/to be issued by Potluri Laboratories Pvt Ltd (another promoter entity), with Avendus PE Investment Advisors (funds managed by Avendus) as the lender. Post this event, Hima Bindu's encumbered shares stand at 1,36,20,000 shares (16.09% of total share capital), and the disclosure explicitly confirms encumbered shares exceed 50% of her individual promoter shareholding and 20% of total share capital. Her earlier pledge of 1,06,20,000 shares (12.55%) for VKT Pharma's NCDs continues. The total promoter group holding remains 64.67% of the company. Funds raised are intended for Potluri Labs' long-term strategic business, working capital, and general corporate purposes.
Creation of a new encumbrance by a promoter, especially where encumbered shares exceed 50% of the individual promoter's holding, is generally a cautious signal for retail investors as it indicates the promoter group is pledging/NDUing shares to raise debt for another group entity. If share prices decline sharply, this could trigger margin calls or forced sale risk. Existing shareholders should monitor the stock for any further encumbrance disclosures.